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Abstract
Introduction We investigated clinical and pathologic features of
breast cancers (BC) in an unselected series of patients
diagnosed in a tertiary care hospital serving a diverse
population. We focused on triple-negative (Tneg) tumours
(oestrogen receptor (ER), progesterone receptor (PR) and
HER2 negative), which are associated with poor prognosis.
Methods We identified female patients with invasive BC
diagnosed between 1998 and 2006, with data available on
tumor grade, stage, ER, PR and HER2 status, and patient age,
body mass index (BMI) and self-identified racial/ethnic group.
We determined associations between patient and tumour
characteristics using contingency tables and multivariate
logistic regression.
Results 415 cases were identified. Patients were racially and
ethnically diverse (born in 44 countries, 36% white, 43% black,
10% Hispanic and 11% other). 47% were obese (BMI > 30 kg/
m2). 72% of tumours were ER+ and/or PR+, 20% were Tneg
and 13% were HER2+. The odds of having a Tneg tumour were
3-fold higher (95% CI 1.6, 5.5; p = 0.0001) in black compared
with white women. Tneg tumours were equally common in black
women diagnosed before and after age 50 (31% vs 29%; p =
NS), and who were obese and non-obese (29% vs 31%; p =
NS). Considering all patients, as BMI increased, the proportion
of Tneg tumours decreased (p = 0.08).
Conclusions Black women of diverse background have 3-fold
more Tneg tumours than non-black women, regardless of age
and BMI. Other factors must determine tumour subtype. The
higher prevalence of Tneg tumours in black women in all age
and weight categories likely contributes to black women's
unfavorable breast cancer prognosis.
Introduction
Breast cancer is a clinically and genetically heterogeneous
disease, varying substantially in incidence and mortality
according to race/ethnicity [1]. To better understand the clini-
cal and pathological features associated with breast cancer,
we created a database of all invasive breast cancer patients
seen at our institution. The Boston University Medical Center
includes a tertiary-care hospital that is the largest safety net
provider in New England and provides care to a diverse popu-
lation. Approximately 75% of patients are insured under gov-
ernment-funded programs (e.g., Medicaid or Medicare) or
receive free care. One-half have an annual income below
$20,420 and 30% do not speak English (medical interpreters
deliver translation in 60 languages). The institution's patients
includes self-identified ethnic groups in the following propor-
tions: 36% black, 32% white, 16% hispanic, 4% Asian and
13% other. "Asian" here includes most South-East Asian
nationalities, except Thailand, Singapore, Taiwan. Those
nationalities, along with Indian, are included in "other".
BMI: body mass index; CI: confidence intervals; EGFR: epidermal growth factor receptor; EMR: electronic medical record; ER: oestrogen receptor; 
FISH: fluorescence in situ hybridisation; HER: human epidermal growth factor receptor; NOS: not otherwise specified; NS: not significant; OR: odds 
ratios; PR: progesterone receptor.
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In the present study, we used the database to examine the inci-
dence of triple-negative breast cancers and their associated
clinical and pathological features.
The triple-negative immunophenotype, that is, oestrogen
receptor (ER), progesterone receptor (PR) and human epider-
mal growth factor receptor (HER) 2 negative, constitutes
approximately 15% of all invasive breast cancers. It is often
categorised as a basal-like tumour, a distinct biological sub-
type identified by gene expression. Many basal-like tumours
express cytokeratins (CK) 5, 6 and 17 as well as HER1 (epi-
dermal growth factor receptor (EGFR) [2]. Basal-like tumours
are associated with aggressive histological features [3],
BRCA mutation carriers [4] and poor prognosis [4,5]. Basal-
like tumours are more common in premenopausal African-
American women compared with postmenopausal African-
American women or non-African-American women [6]. These
reports led us to investigate the proportions of triple-negative
tumours in our ethnically heterogeneous population and to
evaluate whether these triple-negative tumours also belonged
to the basal-like subtype.
In addition, we queried whether body mass index (BMI) was
associated with triple-negative tumours. Elevated BMI has
been shown to be associated with an increased risk of hor-
mone receptor-positive breast cancer in postmenopausal
women [7,8]. In general, obesity has been shown to be asso-
ciated with an increased risk of breast cancer and decreased
survival [9], with a worse prognosis in both pre- and postmen-
opausal women [10,11]. Both white [12-14] and black pre-
menopausal women [15] have modest inverse associations
between body weight and breast cancer incidence [16,17].
Postmenopausal obese women have an increased risk of
developing breast cancer and decreased survival [18,19].
The overall incidence of breast cancer among black women in
the USA is lower than in white women [20]. However, black
women are more likely to have advanced stage of disease at
diagnosis, higher risk of recurrence and worse overall progno-
sis [21-23]. The reasons for this difference are likely to be mul-
tifactorial. Some studies suggest that one factor may be a
variation in obesity and body fat distribution between black
and white women [24-26]. There are few reports on the asso-
ciations between race/ethnicity, BMI, age and breast cancer
subtypes. Reports on the relation between BMI and triple-neg-
ative breast cancer specifically are even fewer. To elucidate
potential relations, we investigated associations between clin-
ical features (race/ethnicity, BMI, age) and tumour character-
istics (grade, ER, PR and HER2 status, nodal involvement).
Materials and methods
Study population
With Institutional Review Board approval, we established a
database of all female patients diagnosed at our institution
with invasive breast cancer between March 1998 and Novem-
ber 2006. Informed consent was waived because individual
patient information was identified only by investigator-gener-
ated code numbers that are not linkable to patient identifiers.
For each patient, we identified tumour grade, stage, level of
ER, PR and HER2 expression (or gene amplification), patient
age, BMI (using standard National Heart, Lung and Blood
Institute categories) and self-identified racial group. Recurrent
tumours were excluded. (Recurrence was defined by time
elapsed since first tumour, interim treatment, immunopheno-
type, histology, metastases and clinical impression). Ten of
415 tumours (2%) were second primary or synchronous con-
tralateral breast tumours and were included in this study.
Data collection
We queried electronic medical records (EMR) and performed
manual medical record review for all patients to ensure quality
control. Tumour histology, grade, stage, ER, PR and HER2
expression were determined from the original pathology
reports. Tumours had been diagnosed by experienced pathol-
ogists using standard criteria for histology and modified
Scarff-Bloom-Richardson criteria for grade. ER and PR
expression were determined using immunoperoxidase staining
(Dako, Carpinteria, CA, USA) and quantified by image analysis
(Biogenex, San Ramon, CA, USA) with values less than 5%
categorised as negative. HER2 expression was determined by
immunohistochemistry (Dako, Carpinteria, CA, USA). Tumours
that showed 2+ Her2/neu immunohistochemistry staining
based on HercepTest criteria were definitively assessed by flu-
orescence in situ hybridisation (FISH) (Vysis, Des Plaines, IL,
USA). Tumours were designated as being HER2+ if they
showed 3+ Her2/neu immunohistochemistry staining (based
on HercepTest criteria) or if they were FISH positive [27,28].
Stage at diagnosis was coded according to the American
Joint Commission on Cancer's Cancer Staging Manual [29].
Patient age at diagnosis was calculated using the dates of
birth and diagnosis in the EMR. Patients were categorised as
diagnosed at age 50 years or younger, when they are more
likely to be premenopausal, or at age over 50 years, when they
are more likely to be postmenopausal. BMI was calculated by
weight (kg)/height squared (m2) using EMR data. In 97% of
cases, weight and height were recorded within six months of
diagnosis. If more than one weight or height value was availa-
ble, we used the values closest to the date of diagnosis.
Patients were placed into one of five BMI categories: under/
normal weight (BMI <25), overweight (BMI 25 to <30), obes-
ity I (BMI 30 to <35), obesity II (BMI 35 to <40) or obesity III
(BMI t 40).
Racial/ethnic group was determined by patient self-identifica-
tion at the time of registration. Categories included: white/cau-
casian, black/African-American, hispanic, Asian/Pacific
Islander, Middle Eastern and other. Due to sparse data,
patients self-identified as Asian or Middle Eastern were
included in the other category. To test the accuracy of the
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registration data, a manual review of the EMR was performed
to determine provider-identified racial/ethnic group. A pro-
vider-identified racial/ethnic group was available for 402 of
415 patients and was concordant with the self-identified
group in 91% of cases. When groups differed, the self-identi-
fied group was used. EMR data often included country of
origin.
Because women born in the Caribbean constituted a large
subgroup of our black population (n = 56, 27%), we com-
pared this subgroup to the rest of the black population, which
comprised patients who were provider-identified as African-
American, African or black without further specification. Our
Caribbean black patients were from countries with a majority
pan-West African origin (Haiti, Jamaica, Trinidad, Tobago, Bar-
bados and Montserrat). Patients from the Caribbean countries
with a majority hispanic origin (Dominican Republic, Puerto
Rico and Cuba) were classified as hispanic and not included
in this black subgroup comparison.
Morphology and immunohistochemistry
For 56 of the 81 triple-negative tumours, residual paraffin-
embedded tumour tissue was available and additional evalua-
tion could be performed. For additional morphological assess-
ment, tumours were classified as grade 2 or grade 3 ductal
carcinoma not otherwise specified (NOS), medullary-like car-
cinoma or other (for example, grade 1 ductal NOS, lobular or
micropapillary tumours). Additional immunohistochemistry
was performed with antibodies to CK 5/6 (Biocare Medical,
Concord, CA, USA), and EGFR (Dako, Carpinteria, CA, USA)
using a streptavidin-biotin horseradish peroxidase detection
kit (Biogenex, San Ramon, CA, USA). The expression of these
markers was graded semi-quantitatively. Allred scoring [30]
was used for CK5/6, with a score of 5 or more considered as
positive. HercepTest scoring criteria [27] were used to grade
EGFR expression, with a score of 2+ or more considered as
positive [31].
Statistical analysis
Data on patient and tumour characteristics were entered into
a Microsoft Excel worksheet (Redmond, WA, USA) and
exported into the SAS (Cary, NC, USA) statistical package.
We used chi-squares statistics based on contingency tables
to test for homogeneity of proportions and multivariate logistic
regression to determine associations between patient-tumour
characteristics and triple-negative breast cancer. Odds ratios
(OR) and 95% confidence intervals (CI) from the multivariate
logistic regression analyses were adjusted for race, BMI and
age (d 50 or > 50). We investigated whether there was an
adjusted association between categorical variables (race and
BMI group) and triple-negative tumour type by calculating
twice the difference in the model log-likelihood with and with-
out the categorical variable. This was distributed as chi-
squared with degrees of freedom equal to the number of cat-
egories less one. Women with missing data were excluded
from these analyses.
Results
Patient characteristics
The demographic features of the 415 patients in our database
are presented in Table 1. Some features are consistent with
averages for the USA, but our population is unusual compared
with most other reported cohorts because of its marked ethnic
and racial diversity (Figure 1). In the present analysis, we
Figure 1
Distribution of breast cancer patients by race/ethnicityibution of breast cancer patients by race/ethnicity. The chart depicts the proportion of patients by race/ethnicity, classifying them by region 
of origin. NOS, not otherwise specified.
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grouped patients into four racial/ethnic categories: white
(36%), black (43%), hispanic (10%) and other (11%). Within
these broad categories, our patient population contained
diverse subcategories. The median age at diagnosis of inva-
sive breast cancer in our patients was 58 years, which is
slightly younger than the US average age of 61 years, as
reported in the National Cancer Institute's SEER Cancer Sta-
tistics Review [32]. Of our patients, 29% were 50 years or
younger and 71% were older than 50 years at diagnosis.
These proportions are generally consistent with US averages
[33]. Notable in our population was the frequency of elevated
BMI (only 23% of women fell into the under/normal weight cat-
egory, while 30% were overweight, 27% were classified as
obesity I, 13% as obesity II and 7% as obesity III).
Table 1
Association between race/ethnicity and clinical-pathological features
Category (p-value)* White Black Hispanic Other All
N (%)
Race 148 (36) 177 (43) 43 (10) 47 (11) 415
Age (years) (0.04)
d50 (premenopausal) 37 (25) 53 (30) 20 (47) 15 (32) 125 (30)
>50 (postmenopausal) 111 (75) 124 (70) 23 (53) 32 (68) 290 (70)
ER positive (0.0003) 115 (80) 104 (59) 35 (81) 35 (74) 289 (70)
PR positive (<0.0001) 105 (72) 90 (51) 36 (84) 22 (47) 253 (62)
Her2 positive (0.03) 11 (7.5) 26 (15) 5 (12) 11 (23) 53 (13)
Triple negative (0.0002) 19 (13) 52 (30) 5 (12) 5 (11) 81 (20)
Grade (0.01)
1 27 (19) 14 (8.5) 7 (16) 6 (13) 54 (14)
2 70 (49) 72 (44) 20 (46) 14 (31) 176 (45)
3 45 (32) 78 (48) 16 (37) 25 (56) 164 (42)
T (tumour size) (0.64)
1 76 (58) 94 (58) 22 (54) 22 (52) 214 (57)
2 44 (33) 56 (35) 12 (29) 15 (36) 127 (34)
3 9 (6.8) 12 (7.4) 6 (15) 4 (9.5) 31 (8)
4 3 (2.3) 0 (0) 1 (2.4) 1 (2.4) 5 (1)
No. of positive nodes (0.50)
0 64 (59) 66 (47) 18 (56) 22 (56) 170 (53)
1 to 3 27 (25) 43 (31) 11 (34) 8 (21) 89 (28)
4 to 9 11 (10) 20 (14) 2 (6) 8 (21) 41 (13)
t 10 6 (6) 11 (8) 1 (3) 1 (3) 19 (6)
BMI (kg/m2) (0.01)
Underweight/normal 39 (27) 32 (18) 5 (12) 19 (40) 95 (23)
Overweight 45 (31) 47 (27) 19 (44) 11 (23) 122 (30)
Obesity I 32 (22) 55 (31) 11 (26) 13 (27) 111 (27)
Obesity II 20 (14) 26 (15) 3 (7) 2 (4.3) 51 (13)
Obesity III 7 (4.9) 15 (8.6) 5 (12) 2 (4.3) 29 (7)
* test of homogeneity of proportions
BMI = body mass index; ER = oestrogen receptor; HER = human epidermal growth factor receptor; PR = progesterone receptor.
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Tumour characteristics
Tumour characteristics are presented in Table 1. Of the 415
invasive breast cancers in our database, 81 (20%) were triple
negative, 297 (72%) were ER and/or PR positive and 53
(13%) were HER2 positive. Overall, our patients had fewer
HER2-positive tumours and more triple-negative tumours than
in some series, although our proportions are consistent with
those in racially/ethnically heterogeneous cohorts [34-36]. In
addition, our patients presented at a somewhat later stage
than average for the USA: 47% of our tumours were lymph
node-positive; the USA average is 39% [32]. However, the
presence of 96 tumours with unconfirmed node status may
have affected these proportions.
We characterised all available triple-negative tumours (56 of
81 (69%)) with additional morphological classification and
immunohistochemical staining for CK5/6 and EGFR to deter-
mine what proportion of the triple-negative tumours had the
basal-like phenotype. We found that 19 of 56 (34%) tumours
were medullary-like, 14 of 56 (25%) were grade 2 and 18 of
56 (32%) were grade 3 ductal carcinoma NOS and 5 of 56
(9%) were of other histologies. Of 56 tumours, 38 (68%) were
CK5/6 and/or EGFR positive. There was a significant associ-
ation between CK5/6 expression and EGFR expression with a
Spearman correlation coefficient of 0.34 (p = 0.01). Taken
together, these studies suggest that our triple-negative
tumours include a high proportion of basal-like tumours.
Patient-tumour associations
We examined associations between race, BMI, age (and pre-
sumed menopausal status), tumour grade, ER expression, PR
expression, HER2 expression and nodal involvement. We con-
firmed previously noted associations between patient and
tumour variables, for example, positive associations between
markers of poor prognosis (e.g., grade and stage). Of particu-
lar relevance, we found in bivariate analyses that obesity was
associated with race (p = 0.01) [15,37] and that triple-nega-
tive status was associated with race (p = 0.0002) [6,34-
36,38,39].
Table 1 shows the associations of race/ethnicity with tumour
prognostic markers and other clinicopathological features. We
noted two associations pertinent to triple-negative tumours
and BMI. First, 30% of tumours in black women were triple
negative, compared with 11 to 13% of tumours in other
women. Second, 55% of black women were obese, compared
with 36 to 45% of other women. There was no substantial
dependence on race/ethnicity categories other than black
(Table 1): the results of our analyses did not substantially
depend on more finely-divided race categories, as determined
by visual examination of the associations and their intervals
with the reference category limited to whites versus the refer-
ence category defined as non-blacks. Therefore, we combined
white, hispanic and other race/ethnicity categories into a sin-
gle category 'non-black', which serves as our reference group,
to address two questions.
Black women were both more likely than other women to be
obese and to have triple-negative tumours, so we asked
whether obese black women had a higher proportion of triple-
negative tumours than other obese women. As shown in Table
2, stratifying the dataset to black vs. non-black women, we
found that 29% of obese black women had triple-negative
tumours compared with 8.6% of obese non-black women (OR
= 4.3: 95 CI = 1.8 to 10; p = 0.0004). (Using whites as the
reference category, the OR = 4.2 and 95% CI = 1.6 to 13).
Similarly, 31% of non-obese black women had triple-negative
tumours compared with 15% of non-obese non-black women
(OR = 2.7, 95% CI = 1.4 to 5.3; p = 0.003). (Using whites as
the reference category, the OR = 2.5 and 95% CI = 1.2 to
5.4). These two ORs were not significantly different from one
another (p = 0.41), suggesting that among black women, BMI
does not appear to be associated with triple-negative status.
Next, we examined associations of age at diagnosis with
tumour characteristics within black and non-black women
(Table 3). In contrast to previous reports [6,40], we did not find
a strong association between triple-negative tumour status
and younger age when we considered all patients (24% triple-
Table 2
Association between triple-negative breast cancer and race/ethnicity within strata of obese and non-obese women.
Black Non-black
n/total (%) n/total (%)
BMI t 30 BMI < 30 BMI t 30 BMI < 30
Tumour immunophenotype
Triple negative 27/94 (29) 25/79 (32) 8/93 (8.6) 20/137 (15)
Other 67/94 (71) 54/79 (68) 85/93 (91) 117/137 (85)
Adjusted odds ratio of triple-negative tumour
(confidence interval)
4.3
(1.8 to 10)
2.7
(1.4 to 5.3)
1.0 1.0
BMI = body mass index.
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negative tumours in women aged d 50 years compared with
18% triple-negative women aged > 50 years; p = 0.22).
Adjustment for more finely divided age categories made no dif-
ference in the estimates of association. We next considered
black vs. non-black women. We found that the proportions of
triple-negative tumours were similar in younger and older black
women: 31% of black women aged 50 years or younger and
29% of black women aged over 50 years had triple-negative
tumours (p = 0.76). In contrast, we found a marginal associa-
tion between triple-negative tumours and age in non-black
women: 17% of non-black women aged 50 years or younger
had triple-negative tumours, compared with 10% of non-black
women aged over 50 years (p = 0.11).
To further characterise the possible relations between race/
ethnicity, BMI and triple-negative breast cancer, we performed
multiple logistic regression analyses. Table 4 shows the
adjusted OR and 95% CI from the multiple logistic regression
analyses for patient characteristics of triple-negative breast
cancers compared with other types of breast cancer. The
odds of having a triple-negative tumour were three-fold higher
(95% CI = 1.6 to 5.4) in black women as compared with white
women. Mutually adjusting for race/ethnicity, BMI and age
(age d 50 years vs. > 50 years, as a surrogate for menopausal
status), there remained a strong association between
race/ethnicity and triple-negative tumours (p = 0.0001). After
adjusting for race/ethnicity and age, we noted decreasing pro-
portions of triple-negative tumours with increasing category of
BMI (p = 0.08).
Because women of Caribbean origin constituted a large pro-
portion of our black population (n = 56, 27%), we compared
Table 3
Associations between patient and tumour characteristics in black vs non-black women diagnosed at age d 50 vs > 50 years
Black Non-black
Patient/tumour characteristic (p-value*) age d50 years
(premenopausal)
age >50 years
(postmenopausal)
age d50 years
(premenopausal)
age >50 years
(postmenopausal)
n (%) n (%) n (%) n (%)
BMI (0.03)
Underweight/normal (<25) 10 (20) 22 (17) 23 (33) 40 (24)
Overweight (25 to <30) 16 (31) 31 (25) 20 (29) 55 (32)
Obesity I (30 to <35) 13 (25) 42 (33) 14 (20) 42 (25)
Obesity II (35 to <40) 4 (7.8) 22 (17) 9 (13) 16 (9.4)
Obesity III (t 40)
Missing
8 (16)
0 (0)
7 (5.6)
2 (1.6)
2 (2.9)
1 (1.5)
12 (7.1)
5 (2.9)
Immunophenotype (<0.0001)
Triple negative 16 (31) 36 (29) 12 (17) 17 (10)
Other
Missing
35 (69)
0 (0)
8 (70)
2 (1.6)
56 (81)
1 (1.5)
151 (89)
2 (1.2)
Grade (0.06)
1 3 (5.9) 11 (8.7) 13 (19) 27 (16)
2 19 (37) 53 (42) 25 (36) 80 (47)
3
Missing
26 (51)
3 (5.9)
52 (41)
10 (7.9)
30 (44)
1 (1.5)
56 (33)
7 (4.1)
Nodal involvement (0.03)
Node negative 13 (25) 48 (38) 31 (45) 51 (30)
Node positive
Missing
29 (57)
9 (18)
52 (41)
26 (21)
30 (43)
8 (12)
71 (42)
48 (28)
Total number (%) of all patients 51 (12) 126 (30) 69 (17) 170 (41)
* test of homogeneity of proportions.
BMI = body mass index.
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this subgroup to the rest of the black population. Controlling
for age (d 50 years vs > 50 years), no significant differences
were seen between Caribbean black women and other black
women in the proportion of triple-negative tumours, BMI,
grade or node involvement (see Additional Data File 1).
Discussion
We investigated clinicopathological features of breast can-
cers in a patient population unusual for its racial/ethnic and
socioeconomic diversity. We focused on triple-negative
tumours. Our results confirmed previously described associa-
tions between patient and tumour characteristics, and uncov-
ered new associations. In particular, we found a three-fold
increased prevalence of triple-negative tumours in black
women, who comprised 43% of our patients compared with
non-black women. Triple-negative tumours comprised equal
fractions – approximately 30% – of breast cancers in younger
and older black women, regardless of their likely menopausal
status. Triple-negative tumours comprised equal fractions –
about 30% – of breast cancers in obese and in non-obese
black women. Considering all women together, regardless of
race/ethnicity and age, we did note a trend toward an inverse
association between triple-negative tumours and elevated
BMI. Overall, these results suggest that black women of
diverse backgrounds are much more likely to be diagnosed
with triple-negative tumours, and therefore a poorer prognosis,
regardless of older age or higher BMI, factors that in other
populations may be associated with hormone receptor-posi-
tive tumours with a better prognosis.
Our observation that both younger and older black women
have increased, equivalent proportions of triple-negative
tumours contrasts with results from the Carolina Breast Can-
cer Study. That study found a higher prevalence of basal-like
tumours only in premenopausal African-American patients [6].
The contrast may be due to the unusual heterogeneity of our
population, with consequent diversity of socioeconomic, life-
style and genetic factors. Our study highlights the complexity
surrounding the issue of race/ethnicity in medical research,
and the potential differences in how each can be defined,
measured and interpreted [41,42]. The contrast could also
reflect differences between the tumours that were studied.
We defined tumours by a triple-negative phenotype and did
not routinely determine if they were basal-like. The triple-nega-
tive tumours we could examine further showed morphological
and immunohistochemical characteristics (i.e., medullary fea-
tures and increased CK5/6 and EGFR staining) in proportions
similar to what has been reported elsewhere, and are consist-
ent with estimates that 80 to 90% of triple-negative tumours
are basal-like [43-45].
Perhaps our most intriguing result is the relation between BMI
and tumour subtype. Existing studies reveal a complicated
relation between BMI and breast cancer. Some studies find
associations between increased BMI and increased risk of
developing breast cancer, higher stage at diagnosis, greater
likelihood of expressing markers of high cell proliferation,
poorer response to neodjuvant chemotherapy and increased
disease-specific mortality [46-51]. On the other hand, there is
Table 4
Adjusted odds ratios for patient characteristics and triple negative immunophenotype
Characteristics predicting
triple negative phenotype
n (%) Adjusted
odds ratio§
95% CI p-value*
Race 0.0001
Black 177 (43) 3.00 1.6 to 5.4
White 148 (36) 1.00 reference
Hispanic 43 (10) 0.83 0.28 to 2.4
Other 47 (11) 0.79 0.27 to 2.3
BMI (kg/m2) 0.08
Underweight/normal (<25) 94 (23) 1.00 reference
Overweight (25 to <30) 123 (30) 1.00 0.51 to 2.1
Obesity I (30 to <35) 111 (27) 0.69 0.33 to 1.5
Obesity II (35 to <40) 51 (13) 0.85 0.35 to 2.07
Obesity III (t 40) 29 (7) 0.86 0.29 to 2.6
Age (years) 0.22
d 50 (premenopausal) 120 (29) 1.40 0.81 to 2.4
> 50 (postmenopausal) 295 (71) 1.00 reference
§adjusted for age, race/ethnicity and BMI; * for test of model with and without the characteristic
BMI = body mass index; CI = confidence interval.
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a clear association between elevated BMI and postmenopau-
sal, ER-positive and PR-positive breast cancers [52], perhaps
due to oestrogen production from adipose tissue. If obesity is
important in determining hormone receptor status, then obese
black and non-black women should have similar proportions of
hormone receptor-negative tumours. However, we find that
obese black women have four-fold more triple-negative
tumours than obese non-black women. Therefore, factors
other than whole body obesity must be crucial in determining
hormone receptor expression. A specific type of obesity, an
elevated waist:hip ratio, was associated with the basal sub-
type in the Carolina dataset [40], but overall, the factors that
determine subtype – genetics, microenvironment, environmen-
tal or developmental exposures – remain unclear.
The lack of association between obesity and hormone recep-
tor expression in black women may contribute to our observa-
tion that, when we considered all 415 cases, we found a trend,
rather than a significant association, between increased BMI
category and decreased proportions of triple-negative
tumours. The inclusion of a large subset of black women
(43%), for whom increased BMI is not clearly associated with
hormone receptor positivity, in the dataset may prevent us
from seeing the association reported in other populations
between increased BMI and hormone receptor positivity.
Our observations are consistent with the lack of association
seen between BMI and overall risk of postmenopausal breast
cancer in the Black Women's Health Study [15]. Those
authors speculated that if obesity confers mainly a risk of hor-
mone receptor-positive tumours, then it would be difficult to
detect an association between elevated BMI and postmeno-
pausal breast cancer if a large proportion of the black
women's cancers were hormone receptor negative. This is
precisely our finding. Our observations are also consistent
with observations that high BMI is associated with hormone
receptor-negative tumours in cohorts of different ethnic com-
position [50,53].
Potential limitations of our study include its relatively small size
and lack of data on clinical outcome or on potential confound-
ers, such as parity. These limitations, however, are balanced
by strengths: the unusual, highly heterogeneous population,
data extraction from computerised records augmented with
manual abstraction for quality control, and a consistent, single-
institution approach to pathological diagnosis and patient
care. Although we do not have the socioeconomic status of
each patient, the population in the database is highly likely to
reflect the institution's overall socioeconomic status data.
These strengths contributed to our database confirming many
previously noted associations between clinical and pathologi-
cal features.
The observations we report from this database have potential
clinical implications. Several studies have documented the
poor outcome of patients with triple-negative or basal-like
tumours [35,38], and the greater mortality of black women
with breast cancer compared with other women, regardless of
age [6,35,38]. Our findings that a diverse group of both
younger and older, normal-weight and obese, black women
have approximately three-fold more triple-negative tumours
than other groups, may be one factor contributing to the unfa-
vourable prognosis of black women with breast cancer.
Conclusion
Black women of diverse background have three-fold more tri-
ple-negative tumours than non-black women, regardless of
age and BMI. Other factors must determine tumour subtype.
The higher prevalence of triple-negative tumours in black
women in all age and weight categories is likely to contribute
to a black women's unfavourable breast cancer prognosis.
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